MicroRNA-146a抑制胶质瘤细胞增殖的研究

目的:检测胶质瘤中miR-146a的表达水平,并研究miR-146a对胶质瘤细胞增殖的影响。方法:应用实时定量PCR的方法检测胶质瘤组织和癌旁组织中miR-146a的表达水平,采用脂质体细胞转染miRNA模拟物的方式过表达miR-146a,MTT法检测转染后细胞的增殖率,利用在线软件targetScan预测miRNA可能的靶基因。结果:miR-146a在胶质瘤组织中表达明显降低(P<0.01),相对表达水平为癌旁组织的35%,细胞转染miR-146a模拟物后,miR-146a表达明显增加,癌细胞增殖率明显降低(P<0.01),仅为原细胞的47%。Notch1基因是miR-146a影响胶质瘤细胞增殖活力的可能靶基因。结论:miR-146a可能通过抑制Notch1基因的表达调控胶质瘤细胞的增殖。     

miR-101抑制凋亡基因调控胰腺癌发生发展的初步研究

目的：研究miR-101在胰腺癌组织中的表达水平及其作用机制。方法：采用实时定量PCR的方法分别检测36例胰腺癌手术切除标本及对应癌旁组织中miR-101的表达水平;运用生物信息学的方法预测其可能的靶基因;通过双荧光素酶报告基因系统验证miR-101与可能靶基因之间的关系。结果：胰腺癌组织中miR-101的表达水平较癌旁组织明显降低（P〈0.01）。生物信息学分析和双荧光素酶报告基因系统结果显示Mcl-1和Ezh2基因可能是miR-101的靶基因。结论：胰腺癌组织中miR-101表达降低,可能通过抑制胰腺癌细胞中Mcl-1和Ezh2基因的表达调控胰腺癌的发生发展。     

miR-449a对人乳腺癌细胞MCF-7增殖及迁移能力的影响

目的：通过敲低微小RNA （microRNA,miRNA）-449a的方法研究miR-449a对人乳腺癌细胞MCF-7的增殖和迁移能力的影响。方法：采用miRNA芯片在乳腺癌细胞MCF-7和人正常乳腺细胞MCF-10A筛选具有表达差异的miRNA;化学合成法制备miR-449a的抑制剂（inhibitor）,转染后经real-time PCR验证表达的变化;细胞增殖CCK-8实验对转染后细胞增殖能力进行检测;划痕实验检测细胞转移能力,transwell小室实验检测细胞侵袭的改变;蛋白免疫印迹法（Western blot）实验对MCF-7细胞增殖和迁移相关的β-catenin和E-cadherin蛋白进行检测;通过生物信息学软件预测miR-449a潜在靶基因为Notch 1,荧光素酶实验检测Notch 1是miR-449a的靶基因。结果：分别收集MCF-7和MCF-10A细胞,芯片结果显示miR-449a在MCF-7细胞的表达水平显著高于MCF-10A;本研究将细胞分为未处理组（Mock组）,阴性对照组（negative control组,NC组）和处理组,通过收集不同组MCF-7细胞进行试验,CCK-8结果显示miR-449a下调后MCF-7细胞增殖能力显著降低;划痕实验结果显示miR-449a表达降低导致MCF-7细胞转移能力降低;transwell实验结果显示MCF-7细胞侵袭受到抑制;Western blot结果发现miR-449a敲低后β-catenin表达降低,E-cadherin表达增加;荧光素酶试验结果显示,miR-449a能够显著降低Notch 1-3'-UTR质粒的荧光素活性（P<0.01）。结论：在乳腺癌细胞MCF-7中敲低miR-449a能够显著抑制癌细胞增殖和迁移,而这一变化可能通过降低Notch 1蛋白表达实现的。     

miR-26a抑制转化生长因子β诱导的韧带成纤维细胞增殖

目的:研究miR-26a对转化生长因子-β(Transforming growth factor-β,TGF-β)诱导的韧带成纤维细胞增殖的影响。方法:原代分离大鼠肩周韧带成纤维细胞,通过免疫荧光鉴定细胞纯度,应用脂质体细胞转染miRNA模拟物的方式过表达miR-26a,定量PCR的方法检测miR-26a模拟物的过表达效率,CCK8法检测细胞增殖能力的变化,生物信息学预测的方法分析miR-26a可能的作用靶基因。结果:免疫荧光检测发现原代分离细胞中,Vimentin阳性细胞在90%以上;转染miR-26a模拟物后,细胞内miR-26a水平显著高于阴性对照组(P0.05);TGF-β刺激明显促进韧带成纤维细胞生长(P0.01),而miR-26a则对TGF-β诱导的韧带成纤维细胞增殖具有显著的抑制作用(P0.01);生物信息学预测显示SMAD1/4、EIF4G2、PTEN和MARK1可能是miR-26a影响细胞增殖的作用靶基因。结论:miR-26a可抑制TGF-β诱导的韧带成纤维细胞增殖。     

miR-26a抑制转化生长因子beta诱导的韧带成纤维细胞增殖

目的:研究miR-26a对转化生长因子-β(Transforming growth factor-β,TGF-β)诱导的韧带成纤维细胞增殖的影响。方法:原代分离大鼠肩周韧带成纤维细胞,通过免疫荧光鉴定细胞纯度,应用脂质体细胞转染miRNA模拟物的方式过表达miR-26a,定量PCR的方法检测miR-26a模拟物的过表达效率,CCK8法检测细胞增殖能力的变化,生物信息学预测的方法分析miR-26a可能的作用靶基因。结果:免疫荧光检测发现原代分离细胞中,Vimentin阳性细胞在90%以上;转染miR-26a模拟物后,细胞内miR-26a水平显著高于阴性对照组(P<0.05);TGF-β刺激明显促进韧带成纤维细胞生长(P<0.01),而miR-26a则对TGF-β诱导的韧带成纤维细胞增殖具有显著的抑制作用(P<0.01);生物信息学预测显示SMAD1/4、EIF4G2、PTEN和MARK1可能是miR-26a影响细胞增殖的作用靶基因。结论:miR-26a可抑制TGF-β诱导的韧带成纤维细胞增殖。     

miR-143在人颈动脉粥样硬化患者斑块组织中表达变化及作用机制

目的探讨miR-143在人颈动脉粥样硬化患者斑块组织中的表达变化及可能的作用机制。方法收集我院血管外科因颈动脉狭窄行颈动脉内膜剥脱术(CEA)切除的颈动脉斑块组织及斑块旁内膜组织56例,根据术前颈动脉超声检查及术后斑块病理学检查将所取得的斑块组织又分为稳定斑块组26例和不稳定斑块组30例。另外选择同期年龄、性别相匹配的在我院因外伤、门脉高压或原发性血小板增多症而行脾脏切除术患者的正常的脾动脉内膜组织20例作为正常对照组,通过实时荧光定量PCR(qRT-PCR)检测组织中miR-143的表达水平。体外培养人主动脉血管平滑肌细胞(HAVSMCs),分别转染mi R-143模拟物、模拟物阴性对照、miR-143抑制物、抑制物阴性对照,采用qRT-PCR检测转染后HAVSMC细胞miR-143表达水平的变化,CCK-8法和Transwell迁移实验分别检测转染后细胞增殖活性和迁移能力的变化。通过生物信息学预测miR-143的可能靶基因,双荧光素酶报告基因实验观察miR-143与ADAMTS4的靶向调控关系,Western blot观察miR-143对ADAMTS4表达水平的影响。结果颈动脉粥样硬化斑块组织中miR-143表达水平明显低于斑块旁内膜组织和正常动脉血管内膜组织,并且不稳定斑块组患者斑块组织中miR-143的表达水平明显低于稳定斑块组斑块组织。转染miR-143模拟物后,HAVSMCs中miR-143表达水平明显升高,增殖活性和迁移能力明显降低;转染miR-143抑制物后,HAVSMCs中miR-143表达水平明显降低,增殖活性和迁移能力明显升高。双荧光素酶报告基因显示ADAMTS4是miR-143的直接靶基因,Western blot显示miR-143能够在转录后水平负向调控ADAMTS4表达。结论 miR-143在颈动脉粥样硬化斑块组织中表达降低,其可能通过靶向调控ADAMTS4影响血管平滑肌细胞增殖和迁移能力,与颈动脉斑块的形成和不稳定性有关。     

miR-182在前列腺癌组织中的表达及其对前列腺癌细胞增殖和凋亡的影响

目的:观察前列腺癌组织及不同前列腺癌细胞系中miR-182的表达,并探讨下调其表达对前列腺癌细胞增殖和凋亡的影响及机制。方法:采用实时荧光定量PCR(q RT-PCR)检测30例前列腺癌组织和30例相应的癌旁组织以及前列腺正常上皮RWPE-1细胞、前列腺癌PC-3、LNCa P和DU145细胞中miR-182的表达,进一步采用Lipfectamine 2000脂质体转染miRNA-182 inhibitor和阴性对照miRNA于PC-3细胞后,通过噻唑蓝(MTT)比色法检测细胞增殖情况,流式细胞术检测细胞凋亡率,免疫印迹(Western blot)法检测转录因子FOXO1、血管内皮生长因子(VEGF)和抑癌基因p53蛋白的表达。结果:miR-182在前列腺癌组织中的表达明显高于癌旁组织(P0.05);miR-182在前列腺癌细胞系PC-3、LNCa P和DU145中的表达均高于前列腺正常上皮细胞RWPE-1(P0.05),其中PC-3细胞中miR-182表达水平最高。转染miRNA-182 inhibitor至PC-3细胞成功下调miR-182表达后,细胞的增殖能力明显受到抑制,细胞凋亡能力明显增强,FOXO1表达水平显著升高,VEGF和p53的表达明显降低,差异均具有统计学意义(P0.05)。结论:miR-182在前列腺癌组织及细胞中呈高表达,下调miR-182的表达可能通过增加FOXO1的表达并减少VEGF和p53的表达,抑制前列腺癌细胞增殖并诱导细胞凋亡。     

人肝细胞癌中PCNA和RAB10水平上调miR-224表达下调

目的为了进一步揭示肝癌发生的分子机理,探讨肝癌中细胞增殖与miR-224、RAB10表达之间的关系。方法选取确诊的肝细胞癌患者8例,手术后分别获得其肝细胞癌和癌旁组织,免疫组织化学检测代表细胞增殖的PCNA和癌基因产物RAB10的表达,实时定量PCR检测miR-224的表达。结果在肝细胞癌中,细胞增殖水平非常显著地高于癌旁组织;miR-224表达显著地低于癌旁组织,但RAB10水平显著高于癌旁组织。结论肝细胞癌发生可能在于肝细胞中下调的miR-224对其靶基因rab10沉默作用降低,使其高水平表达RAB10;高水平RAB10作为细胞癌基因产物促进细胞的增殖、发生肝癌。     

环状RNA circTCF25通过miR-103a-3p/miR-107调控CDK6的表达促进膀胱癌的增殖和迁移

该文旨在探讨环状RNA circTCF25对膀胱癌增殖和迁移的影响。采用RT-q PCR检测膀胱癌及癌旁组织中miR-103a-3p和miR-107的表达水平;采用Western blot和免疫组化检测膀胱癌细胞及膀胱癌和癌旁组织中CDK6的蛋白表达;将circTCF25过表达载体转染两种膀胱癌细胞后,采用RT-q PCR检测细胞中circTCF25以及miR-103a-3p和miR-107的表达水平;采用双荧光素酶报告基因实验验证circTCF25靶向结合miR-107及miR-107的靶基因CDK6;划痕实验检测细胞迁移能力;Edu实验检测细胞增殖能力。RT-q PCR结果表明,膀胱癌组织中miR-103a-3p和miR-107的表达明显低于癌旁组织。免疫组化和Western blot结果显示,膀胱癌组织中CDK6蛋白质水平明显高于癌旁组织。转染circTCF25过表达载体的细胞中,circTCF25的表达水平高于对照组。过表达circTCF25后,细胞中miR-103a-3p和miR-107的表达显著下降,CDK6的蛋白水平增加。双荧光素酶报告基因实验表明,circTCF25可以直接结合miR-107并降低其对靶基因CDK6的抑制。过表达circTCF25后,细胞迁移和增殖能力增强。该研究说明,环状RNA circTCF25可通过miR-103a-3p/miR-107调控CDK6的表达促进膀胱癌的增殖和迁移。     

miR-133a mimics对骨肉瘤细胞系MG63增殖和凋亡作用的影响

目的:研究采用miR-133a mimics瞬时转染骨肉瘤细胞系MG63对其细胞增殖和凋亡作用的影响.方法:采用miR-133a mimics瞬时转染骨肉瘤细胞系MG63,以miR-negative control(NC)mimics作为阴性对照.通过RT-PCR法检测miR-133a在转录水平的表达,CCK法检测其对增殖的影响,采用流式细胞仪检测miR-133a mimics对MG63细胞凋亡作用的影响.利用生物信息学方法预测miR-133a的靶基因,并对其靶基因进行基因功能分析.结果:(1)miR-133a mimics成功转染MG63细胞,并经RT-PCR检测可有效表达.(2)转染48h后,miR-133a mimics组与miR-NC mimics组比较,增值活性明显降低(P＜0.01).(3)miR-133amimics组与miR-NC mimics组和正常细胞相比,其凋亡率显著上升(P＜0.01).(4)生物信息学方法预测miR-133a的靶基因,部分发挥抑制细胞增殖和凋亡的作用.结论:miR-133a对人骨肉瘤细胞MG63的增殖和凋亡能力可能存在调控作用,可能成为骨肉瘤治疗的潜在候选靶点.     

MicroRNA-146a inhibits glioma development by targeting Notch1

Dysregulated epidermal growth factor receptor (EGFR) signaling through either genomic amplification or dominant-active mutation (EGFR(vIII)), in combination with the dual inactivation of INK4A/ARF and PTEN, is a leading cause of gliomagenesis. Our global expression analysis for microRNAs revealed that EGFR activation induces miR-146a expression, which is further potentiated by inactivation of PTEN. Unexpectedly, overexpression of miR-146a attenuates the proliferation, migration, and tumorigenic potential of Ink4a/Arf(-/-) Pten(-/-) Egfr(vIII) murine astrocytes. Its ectopic expression also inhibits the glioma development of a human glioblastoma cell line in an orthotopic xenograft model. Such an inhibitory function of miR-146a on gliomas is largely through downregulation of Notch1, which plays a key role in neural stem cell maintenance and is a direct target of miR-146a. Accordingly, miR-146a modulates neural stem cell proliferation and differentiation and reduces the formation and migration of glioma stem-like cells. Conversely, knockdown of miR-146a by microRNA sponge upregulates Notch1 and promotes tumorigenesis of malignant astrocytes. These findings indicate that, in response to oncogenic cues, miR-146a is induced as a negative-feedback mechanism to restrict tumor growth by repressing Notch1. Our results provide novel insights into the signaling pathways that link neural stem cells to gliomagenesis and may lead to new strategies for treating brain tumors.     

microRNA-214-mediated UBC9 expression in glioma

It has been reported that ubiquitin-conjugating enzyme 9 (Ubc9), the unique enzyme2 in the sumoylation pathway, is up-regulated in many cancers. However, the expression and regulation of UBC9 in glioma remains unknown. In this study, we found that Ubc9 was up-regulated in glioma tissues and cell lines compared to a normal control. UBC9 knockdown by small interfering RNA (siRNA) affected cell proliferation and apoptosis in T98G cells. Further experiments revealed that microRNA (miR)-214 directly targeted the 3'' untranslated region (UTR) of UBC9 and that there was an inverse relationship between the expression levels of miR-214 and UBC9 protein in glioma tissues and cells. miR-214 overexpression suppressed the endogenous UBC9 protein and affected T98G cell proliferation. These findings suggest that miR-214 reduction facilitates UBC9 expression and is involved in the regulation of glioma cell proliferation. [BMB Reports 2012; 45(11): 641-646]     

Inhibiting of circ-TLK1 inhibits the progression of glioma through down-regulating PANX1 via targeting miR-17-5p

Glioma remains the most common malignant tumors in the central nervous system and often has poor prognosis. In recent years, it has been gradually revealed that non-coding RNA effects glioma progression. In this study, we aimed to investigate the significance of circular RNA TLK1 (Circ-TLK1) in predicting the survival of glioma patients as well as its role in glioma development via both in-vitro and in-vivo experiments. We found that Circ-TLK1 was conspicuously up-regulated in glioma tissues compared with adjacent normal tissues, and the up-regulated Circ-TLK1 was significantly correlated with glioma patients’ larger tumor volume and higher grades. Functionally, Circ-TLK1 over-expression facilitated glioma growth, migration and invasion, inhibited cell apoptosis, and accelerated PANX1/MAPK/ERK expression, while Circ-TLK1 low expression had the opposite effects. In addition, bioinformatics analysis showed that miR-17-5p was a potential target of Circ-TLK1 and targeted at PANX1. Furthermore, through dual luciferase viability assay, Circ-TLK1 acted as a competing endogenous RNA by sponging miR-17-5p, which targeted and inhibited PANX1/MAPK/ERK expression. MiR-17-5p overexpression mitigated glioma progression, which was significantly inhibited with Circ-TLK1 upregulation. In conclusion, this study confirmed a novel axis of Circ-TLK1-miR-17-5p-PANX1 in modulating glioma development, providing more references for glioma diagnosis and targeted therapy.

     

miR-1254 inhibits progression of glioma in vivo and in vitro by targeting CSF-1

The role of miRNAs (microRNAs) has been implicated in glioma initiation and progression, although the inherent biochemical mechanisms still remain to be unravelled. This study strived to evaluate the association between CSF-1 and miR-1254 and their effect on advancement of glioma cells. The levels of miR-1254 in glioma cells and tissues were determined by real-time RT-PCR. Proliferation, apoptosis and cell cycle arrest, invasion and migration, were assessed by CCK-8 assay, colony formation assay, flow cytometry, transwell assay and wound-healing assay, respectively. The targeted relationship between miR-1254 and CSF-1 was confirmed by dual-luciferase reporter assay. The effects of CSF-1 on cellular functions were also assessed. The in vivo effect of miR-1254 on the formation of a tumour was explored by using the mouse xenograft model. We found in both glioma tissues and glioma cells, the down-regulated expressions of miR-1254 while that of CSF-1 was abnormally higher than normal level. The target relationship between CSF-1 and miR-1254 was validated by dual-luciferase reporter assay. The CSF-1 down-regulation or miR-1254 overexpression impeded the invasion, proliferation and migratory ability of U251 and U87 glioma cells, concurrently occluded the cell cycle and induced cell apoptosis. Moreover, in vivo tumour development was repressed due to miR-1254 overexpression. Thus, CSF-1 is targeted directly by miR-1254, and the miR-1254/CSF-1 axis may be a potential diagnostic target for malignant glioma.     

Extracellular vesicle-derived microRNA-18b ameliorates preeclampsia by enhancing trophoblast proliferation and migration via Notch2/TIM3/mTORC1 axis

Preeclampsia (PE), a common disorder of pregnancy, is characterized by insufficient trophoblast migration and inadequate vascular remodelling, such that promotion of trophoblast proliferation might ameliorate PE. In the current study, we sought to study the underlying mechanism of extracellular vesicle (EV)-derived microRNA-18 (miR-18b) in PE. Human umbilical cord mesenchymal stem cells (HUCMSCs) isolated from placental tissues were verified through osteogenic, adipogenic and chondrogenic differentiation assays. Bioinformatics analyses and dual-luciferase reporter gene assay were adopted to confirm the targeting relationship between miR-18b and Notch2. The functional roles of EV-derived miR-18b and Notch2 in trophoblasts were determined using loss- and gain-of-function experiments, and trophoblast proliferation and migration were assayed using CCK-8 and Transwell tests. In vivo experiments were conducted to determine the effect of EV-derived miR-18b, Notch2 and TIM3/mTORC1 in a rat model of PE, with monitoring of blood pressure and urine proteinuria. TUNEL staining was conducted to observe the cell apoptosis of placental tissues of PE rats. We found down-regulated miR-18b expression, and elevated Notch2, TIM3 and mTORC1 levels in the placental tissues of PE patients compared with normal placenta. miR-18b was delivered to trophoblasts and targeted Notch2 and negatively its expression, whereas Notch2 positively mediated the expression of TIM3/mTORC1. EV-derived miR-18b or Notch2 down-regulation enhanced trophoblast proliferation and migration in vitro and decreased blood pressure and 24 hours urinary protein in PE rats by deactivating the TIM3/mTORC1 axis in vivo. In summary, EV-derived miR-18b promoted trophoblast proliferation and migration via down-regulation of Notch2-dependent TIM3/mTORC1.     

miR-215 functions as an oncogene in high-grade glioma by regulating retinoblastoma 1

Objectives

To investigate the roles of miR-215 in high-grade glioma and to clarify the regulation of retinoblastoma 1 (RB1) by miR-215.

Results

miR-215 is frequently up-regulated in high-grade glioma tissues. Increased miR-215 expression is significantly associated with World Health Organization grade (P < 0.01) tumor size (P < 0.05) and poor prognosis (P < 0.01). Over-expression of miR-215 promoted cell proliferation and knockdown of miR-215 inhibited cell proliferation in vitro. RB1 was identified as a direct and functional target of miR-215. RB1 is generally down-regulated in glioma tissues and its expression inversely correlated with miR-215, which is up-regulated in high-grade glioma tissues, and its expression was negatively correlated with miR-215.

Conclusions

The new miR-215/RB1 axis provides new insights into the molecular mechanism and treatment for glioma.

     

SIK1作为miR-93新的靶基因抑制前列腺癌细胞增殖、侵袭和迁移

该文探讨了SIK1作为miR-93新的靶基因对前列腺癌细胞增殖、侵袭和迁移的抑制作用.采用重组质粒pcDNA3.1-SIK1上调前列腺癌细胞中SIK1的表达后,利用CCK8和克隆形成实验检测细胞增殖;利用细胞划痕和Transwell实验检测细胞侵袭和迁移;利用West-ern blot检测E-cadherin和Vime...